Targeted pharmacological therapy restores β-cell function for diabetes remission.


Journal

Nature metabolism
ISSN: 2522-5812
Titre abrégé: Nat Metab
Pays: Germany
ID NLM: 101736592

Informations de publication

Date de publication:
02 2020
Historique:
received: 31 07 2019
accepted: 15 01 2020
entrez: 23 7 2020
pubmed: 23 7 2020
medline: 20 1 2021
Statut: ppublish

Résumé

Dedifferentiation of insulin-secreting β cells in the islets of Langerhans has been proposed to be a major mechanism of β-cell dysfunction. Whether dedifferentiated β cells can be targeted by pharmacological intervention for diabetes remission, and ways in which this could be accomplished, are unknown as yet. Here we report the use of streptozotocin-induced diabetes to study β-cell dedifferentiation in mice. Single-cell RNA sequencing (scRNA-seq) of islets identified markers and pathways associated with β-cell dedifferentiation and dysfunction. Single and combinatorial pharmacology further show that insulin treatment triggers insulin receptor pathway activation in β cells and restores maturation and function for diabetes remission. Additional β-cell selective delivery of oestrogen by Glucagon-like peptide-1 (GLP-1-oestrogen conjugate) decreases daily insulin requirements by 60%, triggers oestrogen-specific activation of the endoplasmic-reticulum-associated protein degradation system, and further increases β-cell survival and regeneration. GLP-1-oestrogen also protects human β cells against cytokine-induced dysfunction. This study not only describes mechanisms of β-cell dedifferentiation and regeneration, but also reveals pharmacological entry points to target dedifferentiated β cells for diabetes remission.

Identifiants

pubmed: 32694693
doi: 10.1038/s42255-020-0171-3
pii: 10.1038/s42255-020-0171-3
doi:

Substances chimiques

Estrogens 0
Hypoglycemic Agents 0
Insulin 0
Streptozocin 5W494URQ81
Glucagon-Like Peptide 1 89750-14-1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

192-209

Commentaires et corrections

Type : ErratumIn

Références

Matveyenko, A. V. & Butler, P. C. Relationship between β-cell mass and diabetes onset. Diabetes Obes. Metab. 10, 23–31 (2008).
pubmed: 18834430 pmcid: 3375862 doi: 10.1111/j.1463-1326.2008.00939.x
Herold, K. C. et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N. Engl. J. Med. 381, 603–613 (2019).
pubmed: 31180194 pmcid: 6776880 doi: 10.1056/NEJMoa1902226
Harrison, L. B., Adams-Huet, B., Raskin, P. & Lingvay, I. β-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care 35, 1406–1412 (2012).
pubmed: 22723578 pmcid: 3379585 doi: 10.2337/dc11-2170
Chen, H.-S. et al. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 31, 1927–1932 (2008).
pubmed: 18556343 pmcid: 2551629 doi: 10.2337/dc08-0075
The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the diabetes control and complications trial: a randomized, controlled trial. Ann. Intern. Med. 128, 517–523.
Weng, J. et al. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. The Lancet 371, 1753–1760 (2008).
doi: 10.1016/S0140-6736(08)60762-X
Alvarsson, M. et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 26, 2231–2237 (2003).
pubmed: 12882841 doi: 10.2337/diacare.26.8.2231
Rui, J. et al. β cells that resist immunological attack develop during progression of autoimmune diabetes in NOD mice. Cell Metab. 25, 727–738 (2017).
pubmed: 28190773 pmcid: 5342930 doi: 10.1016/j.cmet.2017.01.005
Talchai, C., Xuan, S., Lin, H. V., Sussel, L. & Accili, D. Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure. Cell 150, 1223–1234 (2012).
pubmed: 22980982 pmcid: 3445031 doi: 10.1016/j.cell.2012.07.029
Cinti, F. et al. Evidence of β-cell dedifferentiation in human type 2 diabetes. J. Clin. Endocrinol. Metab. 101, 1044–1054 (2016).
pubmed: 26713822 doi: 10.1210/jc.2015-2860
Like, A. A. & Rossini, A. A. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 193, 415–417 (1976).
pubmed: 180605 doi: 10.1126/science.180605
Thorel, F. et al. Conversion of adult pancreatic α-cells to β-cells after extreme β-cell loss. Nature 464, 1149–1154 (2010).
pubmed: 20364121 pmcid: 2877635 doi: 10.1038/nature08894
Chera, S. et al. Diabetes recovery by age-dependent conversion of pancreatic δ-cells into insulin producers. Nature 514, 503–507 (2014).
pubmed: 25141178 pmcid: 4209186 doi: 10.1038/nature13633
Brereton, M. F. et al. Reversible changes in pancreatic islet structure and function produced by elevated blood glucose. Nat. Commun. 5, 4639 (2014).
pubmed: 25145789 doi: 10.1038/ncomms5639
Wang, Z., York, N. W., Nichols, C. G. & Remedi, M. S. Pancreatic β cell dedifferentiation in diabetes and redifferentiation following insulin therapy. Cell Metab. 19, 872–882 (2014).
pubmed: 24746806 pmcid: 4067979 doi: 10.1016/j.cmet.2014.03.010
Tiano, J. P. & Mauvais-Jarvis, F. Importance of oestrogen receptors to preserve functional β-cell mass in diabetes. Nat. Rev. Endocrinol. 8, 342–351 (2012).
pubmed: 22330739 doi: 10.1038/nrendo.2011.242
Chon, S. & Gautier, J.-F. An update on the effect of incretin-based therapies on β-cell function and mass. Diabetes Metab. J. 40, 99–114 (2016).
pubmed: 27126881 pmcid: 4853229 doi: 10.4093/dmj.2016.40.2.99
Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834–1844 (2016).
pubmed: 27633186 doi: 10.1056/NEJMoa1607141
Finan, B. et al. Targeted estrogen delivery reverses the metabolic syndrome. Nat. Med. 18, 1847–1856 (2012).
pubmed: 23142820 pmcid: 3757949 doi: 10.1038/nm.3009
Clemmensen, C. et al. Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases. Nat. Rev. Endocrinol. 15, 90–104 (2019).
pubmed: 30446744 doi: 10.1038/s41574-018-0118-x
Bastidas-Ponce, A. et al. Foxa2 and Pdx1 cooperatively regulate postnatal maturation of pancreatic β-cells. Mol. Metab. 6, 524–534 (2017).
pubmed: 28580283 pmcid: 5444078 doi: 10.1016/j.molmet.2017.03.007
Blum, B. et al. Functional beta-cell maturation is marked by an increased glucose threshold and by expression of urocortin 3. Nat. Biotechnol. 30, 261–264 (2012).
pubmed: 22371083 pmcid: 4617627 doi: 10.1038/nbt.2141
Nishimura, W. et al. A switch from MafB to MafA expression accompanies differentiation to pancreatic beta-cells. Dev. Biol. 293, 526–539 (2006).
pubmed: 16580660 pmcid: 2390934 doi: 10.1016/j.ydbio.2006.02.028
Bader, E. et al. Identification of proliferative and mature β-cells in the islets of Langerhans. Nature 535, 430–434 (2016).
pubmed: 27398620 doi: 10.1038/nature18624
Roscioni, S. S., Migliorini, A., Gegg, M. & Lickert, H. Impact of islet architecture on β-cell heterogeneity, plasticity and function. Nat. Rev. Endocrinol. 12, 695–709 (2016).
pubmed: 27585958 doi: 10.1038/nrendo.2016.147
Ediger, B. N. et al. Islet-1 is essential for pancreatic β-cell function. Diabetes 63, 4206–4217 (2014).
pubmed: 25028525 pmcid: 4237994 doi: 10.2337/db14-0096
Gao, T. et al. Pdx1 maintains β cell identity and function by repressing an α cell program. Cell Metab. 19, 259–271 (2014).
pubmed: 24506867 pmcid: 3950964 doi: 10.1016/j.cmet.2013.12.002
Gu, C. et al. Pancreatic β cells require NeuroD to achieve and maintain functional maturity. Cell Metab. 11, 298–310 (2010).
pubmed: 20374962 pmcid: 2855640 doi: 10.1016/j.cmet.2010.03.006
Gutiérrez, G. D. et al. Pancreatic β cell identity requires continual repression of non–β cell programs. J. Clin. Invest. 127, 244–259 (2016).
pubmed: 27941248 pmcid: 5199704 doi: 10.1172/JCI88017
Swisa, A. et al. PAX6 maintains β cell identity by repressing genes of alternative islet cell types. J. Clin. Invest. 127, 230–243 (2016).
pubmed: 27941241 pmcid: 5199694 doi: 10.1172/JCI88015
Taylor, B. L., Liu, F.-F. & Sander, M. Nkx6.1 is essential for maintaining the functional state of pancreatic beta cells. Cell Rep. 4, 1262–1275 (2013).
pubmed: 24035389 pmcid: 4058003 doi: 10.1016/j.celrep.2013.08.010
Kim-Muller, J. Y. et al. Aldehyde dehydrogenase 1a3 defines a subset of failing pancreatic β cells in diabetic mice. Nat. Commun. 7, 12631 (2016).
pubmed: 27572106 pmcid: 5013715 doi: 10.1038/ncomms12631
Dahan, T. et al. Pancreatic β-cells express the fetal islet hormone gastrin in rodent and human diabetes. Diabetes 66, 426–436 (2017).
pubmed: 27864307 doi: 10.2337/db16-0641
Solimena, M. et al. Systems biology of the IMIDIA biobank from organ donors and pancreatectomised patients defines a novel transcriptomic signature of islets from individuals with type 2 diabetes. Diabetologia 61, 641–657 (2018).
pubmed: 29185012 doi: 10.1007/s00125-017-4500-3
Camunas-Soler, J.et al. Pancreas patch-seq links physiologic dysfunction in diabetes to single-cell transcriptomic phenotypes. Preprint at bioRxiv https://doi.org/10.1101/555110 (2019).
Weir, G. C. & Bonner-Weir, S. Islet β cell mass in diabetes and how it relates to function, birth, and death: islet β cell mass in diabetes. Ann. N. Y. Acad. Sci. 1281, 92–105 (2013).
pubmed: 23363033 pmcid: 3618572 doi: 10.1111/nyas.12031
Qiu, W.-L. et al. Deciphering pancreatic islet β cell and α cell maturation pathways and characteristic features at the single-cell level. Cell Metab. 25, 1194–1205.e4 (2017).
pubmed: 28467935 doi: 10.1016/j.cmet.2017.04.003
Taniguchi, C. M., Emanuelli, B. & Kahn, C. R. Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 7, 85–96 (2006).
pubmed: 16493415 doi: 10.1038/nrm1837
Rowlands, J., Heng, J., Newsholme, P. & Carlessi, R. Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function. Front. Endocrinol. 9, 672 (2018).
doi: 10.3389/fendo.2018.00672
Segars, J. H. & Driggers, P. H. Estrogen action and cytoplasmic signaling cascades. Part I: membrane-associated signaling complexes. Trends Endocrinol. Metab. 13, 349–354 (2002).
pubmed: 12217492 pmcid: 4137481 doi: 10.1016/S1043-2760(02)00633-1
Hancock, M. L. et al. Insulin receptor associates with promoters genome-wide and regulates gene expression. Cell 177, 722–736.e22 (2019).
pubmed: 30955890 pmcid: 6478446 doi: 10.1016/j.cell.2019.02.030
Kulkarni, R. N. et al. Altered function of insulin receptor substrate-1–deficient mouse islets and cultured β-cell lines. J. Clin. Invest. 104, R69–R75 (1999).
pubmed: 10606633 pmcid: 409887 doi: 10.1172/JCI8339
Ueki, K. et al. Total insulin and IGF-I resistance in pancreatic β cells causes overt diabetes. Nat. Genet. 38, 583–588 (2006).
pubmed: 16642022 doi: 10.1038/ng1787
Fonseca, S. G., Gromada, J. & Urano, F. Endoplasmic reticulum stress and pancreatic β-cell death. Trends Endocrinol. Metab. 22, 266–274 (2011).
pubmed: 21458293 pmcid: 3130122
Sims, E. K. et al. Elevations in the fasting serum proinsulin-to-C-peptide ratio precede the onset of type 1 diabetes. Diabetes Care 39, 1519–1526 (2016).
pubmed: 27385327 pmcid: 5001142 doi: 10.2337/dc15-2849
Xu, B. et al. Estrogens promote misfolded proinsulin degradation to protect insulin production and delay diabetes. Cell Rep. 24, 181–196 (2018).
pubmed: 29972779 pmcid: 6092934 doi: 10.1016/j.celrep.2018.06.019
Tiwari, A. et al. SDF2L1 interacts with the ER-associated degradation machinery and retards the degradation of mutant proinsulin in pancreatic β-cells. J. Cell Sci. 126, 1962–1968 (2013).
pubmed: 23444373
Ho, D. V. & Chan, J. Y. Induction of Herpud1 expression by ER stress is regulated by Nrf1. FEBS Lett. 589, 615–620 (2015).
pubmed: 25637874 doi: 10.1016/j.febslet.2015.01.026
Wong, N., Morahan, G., Stathopoulos, M., Proietto, J. & Andrikopoulos, S. A novel mechanism regulating insulin secretion involving Herpud1 in mice. Diabetologia 56, 1569–1576 (2013).
pubmed: 23620059 doi: 10.1007/s00125-013-2908-y
Belmont, P. J. et al. Roles for endoplasmic reticulum-associated degradation and the novel endoplasmic reticulum stress response gene Derlin-3 in the ischemic heart. Circ. Res. 106, 307–316 (2010).
pubmed: 19940266 doi: 10.1161/CIRCRESAHA.109.203901
Zhu, D. et al. Single-cell transcriptome analysis reveals estrogen signaling coordinately augments one-carbon, polyamine, and purine synthesis in breast cancer. Cell Rep. 25, 2285–2298.e4 (2018).
pubmed: 30463022 doi: 10.1016/j.celrep.2018.10.093
Torrent, M., Chalancon, G., de Groot, N. S., Wuster, A. & Madan Babu, M. Cells alter their tRNA abundance to selectively regulate protein synthesis during stress conditions. Sci. Signal. 11, eaat6409 (2018).
pubmed: 30181241 pmcid: 6130803 doi: 10.1126/scisignal.aat6409
Xu, G. et al. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 56, 1551–1558 (2007).
pubmed: 17360984 doi: 10.2337/db06-1033
Fritsche, A., Stefan, N., Hardt, E., Häring, H. & Stumvoll, M. Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion. Diabetologia 43, 852–858 (2000).
pubmed: 10952457 doi: 10.1007/s001250051461
Kjems, L. L., Holst, J. J., Vølund, A. & Madsbad, S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52, 380–386 (2003).
pubmed: 12540611 doi: 10.2337/diabetes.52.2.380
Jonas, J. C. et al. Chronic hyperglycemia triggers loss of pancreatic beta cell differentiation in an animal model of diabetes. J. Biol. Chem. 274, 14112–14121 (1999).
pubmed: 10318828 doi: 10.1074/jbc.274.20.14112
Keenan, H. A. et al. Residual insulin production and pancreatic β-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 59, 2846–2853 (2010).
pubmed: 20699420 pmcid: 2963543 doi: 10.2337/db10-0676
Lam, C. J., ChatterjeeA., ShenE., Cox, A. R. & Kushner, J. A. Low-level insulin content within abundant non-á islet endocrine cells in long-standing type 1 diabetes. Diabetes 68, 598–608 (2019).
pubmed: 30552110 doi: 10.2337/db18-0305
Seiron, P. et al. Characterisation of the endocrine pancreas in type 1 diabetes: islet size is maintained but islet number is markedly reduced. J. Pathol. Clin. Res. 5, 248–255 (2019).
pubmed: 31493350 pmcid: 6817830 doi: 10.1002/cjp2.140
Zhou, Q. & Melton, D. A. Pancreas regeneration. Nature 557, 351–358 (2018).
pubmed: 29769672 pmcid: 6168194 doi: 10.1038/s41586-018-0088-0
Waaseth, M. et al. Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer postgenome cohort: a cross-sectional analysis. BMC Womens Health 8, 1 (2008).
pubmed: 18194511 pmcid: 2254595 doi: 10.1186/1472-6874-8-1
Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 19, 15 (2018).
pubmed: 29409532 pmcid: 5802054 doi: 10.1186/s13059-017-1382-0
Büttner, M., Miao, Z., Wolf, F. A., Teichmann, S. A. & Theis, F. J. A test metric for assessing single-cell RNA-seq batch correction. Nat. Methods 16, 43–49 (2019).
pubmed: 30573817 doi: 10.1038/s41592-018-0254-1
Wolf, F. A. et al. PAGA: graph abstraction reconciles clustering with trajectory inference through a topology preserving map of single cells. Genome Biol. 20, 59 (2019).
pubmed: 30890159 pmcid: 6425583 doi: 10.1186/s13059-019-1663-x
Blondel, V. D., Guillaume, J.-L., Lambiotte, R. & Lefebvre, E. Fast unfolding of communities in large networks. J. Stat. Mech. Theory Exp. 2008, P10008 (2008).
doi: 10.1088/1742-5468/2008/10/P10008
Becht, E. et al. Dimensionality reduction for visualizing single-cell data using UMAP. Nat. Biotechnol. 37, 38–44 (2018).
doi: 10.1038/nbt.4314
Chiang, M.-K. & Melton, D. A. Single-cell transcript analysis of pancreas development. Dev. Cell 4, 383–393 (2003).
pubmed: 12636919 doi: 10.1016/S1534-5807(03)00035-2
Katsuta, H. et al. Single pancreatic beta cells co-express multiple islet hormone genes in mice. Diabetologia 53, 128–138 (2010).
pubmed: 19851748 doi: 10.1007/s00125-009-1570-x
Alpert, S., Hanahan, D. & Teitelman, G. Hybrid insulin genes reveal a developmental lineage for pancreatic endocrine cells and imply a relationship with neurons. Cell 53, 295–308 (1988).
pubmed: 3282675 doi: 10.1016/0092-8674(88)90391-1
Zheng, G. X. Y. et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).
pubmed: 28091601 pmcid: 5241818 doi: 10.1038/ncomms14049
Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: computational identification of cell doublets in single-cell transcriptomic data. Cell Syst. 8, 281–291.e9 (2019).
pubmed: 30954476 pmcid: 6625319 doi: 10.1016/j.cels.2018.11.005
Kowalczyk, M. S. et al. Single-cell RNA-seq reveals changes in cell cycle and differentiation programs upon aging of hematopoietic stem cells. Genome Res. 25, 1860–1872 (2015).
pubmed: 26430063 pmcid: 4665007 doi: 10.1101/gr.192237.115
Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189–196 (2016).
pubmed: 27124452 pmcid: 4944528 doi: 10.1126/science.aad0501
Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33, 495–502 (2015).
pubmed: 25867923 pmcid: 4430369 doi: 10.1038/nbt.3192
Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).
pubmed: 24485249 pmcid: 4053721 doi: 10.1186/gb-2014-15-2-r29
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47–e47 (2015).
pubmed: 25605792 pmcid: 4402510 doi: 10.1093/nar/gkv007
Soneson, C. & Robinson, M. D. Bias, robustness and scalability in single-cell differential expression analysis. Nat. Methods 15, 255–261 (2018).
doi: 10.1038/nmeth.4612 pubmed: 29481549
Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90–W97 (2016).
pubmed: 27141961 pmcid: 4987924 doi: 10.1093/nar/gkw377
Haghverdi, L., Büttner, M., Wolf, F. A., Buettner, F. & Theis, F. J. Diffusion pseudotime robustly reconstructs lineage branching. Nat. Methods 13, 845–848 (2016).
doi: 10.1038/nmeth.3971 pubmed: 27571553
Tritschler, S. et al. Concepts and limitations for learning developmental trajectories from single cell genomics. Development 146, dev170506 (2019).
pubmed: 31249007 doi: 10.1242/dev.170506
Polański, K. et al. BBKNN: fast batch alignment of single cell transcriptomes. Bioinformatics 36, 964–965 (2019).
La Manno, G. et al. RNA velocity of single cells. Nature 560, 494–498 (2018).
pubmed: 30089906 pmcid: 6130801 doi: 10.1038/s41586-018-0414-6

Auteurs

Stephan Sachs (S)

Institute of Diabetes and Regeneration Research, Helmholtz Diabetes Center, Helmholtz Center Munich, Neuherberg, Germany.
Institute of Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Center Munich, Neuherberg, Germany.
Division of Metabolic Diseases, Department of Medicine, Technical University of Munich, Munich, Germany.
German Center for Diabetes Research (DZD), Neuherberg, Germany.

Aimée Bastidas-Ponce (A)

Institute of Diabetes and Regeneration Research, Helmholtz Diabetes Center, Helmholtz Center Munich, Neuherberg, Germany.
German Center for Diabetes Research (DZD), Neuherberg, Germany.
Institute of Stem Cell Research, Helmholtz Center Munich, Neuherberg, Germany.
Department of Medicine, Technical University of Munich, Munich, Germany.

Sophie Tritschler (S)

Institute of Diabetes and Regeneration Research, Helmholtz Diabetes Center, Helmholtz Center Munich, Neuherberg, Germany.
German Center for Diabetes Research (DZD), Neuherberg, Germany.
Institute of Computational Biology, Helmholtz Center Munich, Neuherberg, Germany.
School of Life Sciences Weihenstephan, Technical University of Munich, Freising, Germany.

Mostafa Bakhti (M)

Institute of Diabetes and Regeneration Research, Helmholtz Diabetes Center, Helmholtz Center Munich, Neuherberg, Germany.
German Center for Diabetes Research (DZD), Neuherberg, Germany.
Institute of Stem Cell Research, Helmholtz Center Munich, Neuherberg, Germany.

Anika Böttcher (A)

Institute of Diabetes and Regeneration Research, Helmholtz Diabetes Center, Helmholtz Center Munich, Neuherberg, Germany.
German Center for Diabetes Research (DZD), Neuherberg, Germany.
Institute of Stem Cell Research, Helmholtz Center Munich, Neuherberg, Germany.

Miguel A Sánchez-Garrido (MA)

Institute of Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Center Munich, Neuherberg, Germany.

Marta Tarquis-Medina (M)

Institute of Diabetes and Regeneration Research, Helmholtz Diabetes Center, Helmholtz Center Munich, Neuherberg, Germany.
German Center for Diabetes Research (DZD), Neuherberg, Germany.
Institute of Stem Cell Research, Helmholtz Center Munich, Neuherberg, Germany.
Department of Medicine, Technical University of Munich, Munich, Germany.

Maximilian Kleinert (M)

Institute of Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Center Munich, Neuherberg, Germany.
Section of Molecular Physiology, Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.

Katrin Fischer (K)

Institute of Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Center Munich, Neuherberg, Germany.
Division of Metabolic Diseases, Department of Medicine, Technical University of Munich, Munich, Germany.

Sigrid Jall (S)

Institute of Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Center Munich, Neuherberg, Germany.
Division of Metabolic Diseases, Department of Medicine, Technical University of Munich, Munich, Germany.

Alexandra Harger (A)

Institute of Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Center Munich, Neuherberg, Germany.

Erik Bader (E)

Institute of Diabetes and Regeneration Research, Helmholtz Diabetes Center, Helmholtz Center Munich, Neuherberg, Germany.

Sara Roscioni (S)

Institute of Diabetes and Regeneration Research, Helmholtz Diabetes Center, Helmholtz Center Munich, Neuherberg, Germany.

Siegfried Ussar (S)

German Center for Diabetes Research (DZD), Neuherberg, Germany.
Department of Medicine, Technical University of Munich, Munich, Germany.
RG Adipocytes & Metabolism, Institute for Diabetes & Obesity, Helmholtz Diabetes Center, Helmholtz Center Munich, Neuherberg, Germany.

Annette Feuchtinger (A)

Research Unit Analytical Pathology, Helmholtz Center Munich, Neuherberg, Germany.

Burcak Yesildag (B)

InSphero AG, Schlieren, Switzerland.

Aparna Neelakandhan (A)

InSphero AG, Schlieren, Switzerland.

Christine B Jensen (CB)

Global Drug Discovery, Novo Nordisk A/S, Maaloev, Denmark.

Marion Cornu (M)

Global Drug Discovery, Novo Nordisk A/S, Maaloev, Denmark.

Bin Yang (B)

Novo Nordisk Research Center Indianapolis, Indianapolis, IN, USA.

Brian Finan (B)

Novo Nordisk Research Center Indianapolis, Indianapolis, IN, USA.

Richard D DiMarchi (RD)

Novo Nordisk Research Center Indianapolis, Indianapolis, IN, USA.
Department of Chemistry, Indiana University, Bloomington, IN, USA.

Matthias H Tschöp (MH)

Institute of Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Center Munich, Neuherberg, Germany.
Division of Metabolic Diseases, Department of Medicine, Technical University of Munich, Munich, Germany.
German Center for Diabetes Research (DZD), Neuherberg, Germany.

Fabian J Theis (FJ)

Institute of Computational Biology, Helmholtz Center Munich, Neuherberg, Germany. fabian.theis@helmholtz-muenchen.de.
School of Life Sciences Weihenstephan, Technical University of Munich, Freising, Germany. fabian.theis@helmholtz-muenchen.de.
Department of Mathematics, Technical University of Munich, Munich, Germany. fabian.theis@helmholtz-muenchen.de.

Susanna M Hofmann (SM)

Institute of Diabetes and Regeneration Research, Helmholtz Diabetes Center, Helmholtz Center Munich, Neuherberg, Germany. susanna.hofmann@helmholtz-muenchen.de.
German Center for Diabetes Research (DZD), Neuherberg, Germany. susanna.hofmann@helmholtz-muenchen.de.
Medical Clinic and Polyclinic IV, Ludwig Maximilian University of Munich, Munich, Germany. susanna.hofmann@helmholtz-muenchen.de.

Timo D Müller (TD)

Institute of Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Center Munich, Neuherberg, Germany. timo.mueller@helmholtz-muenchen.de.
German Center for Diabetes Research (DZD), Neuherberg, Germany. timo.mueller@helmholtz-muenchen.de.
Department of Pharmacology and Experimental Therapy, Institute of Experimental and Clinical Pharmacology and Toxicology, Eberhard Karls University Hospitals and Clinics, Tübingen, Germany. timo.mueller@helmholtz-muenchen.de.

Heiko Lickert (H)

Institute of Diabetes and Regeneration Research, Helmholtz Diabetes Center, Helmholtz Center Munich, Neuherberg, Germany. heiko.lickert@helmholtz-muenchen.de.
German Center for Diabetes Research (DZD), Neuherberg, Germany. heiko.lickert@helmholtz-muenchen.de.
Institute of Stem Cell Research, Helmholtz Center Munich, Neuherberg, Germany. heiko.lickert@helmholtz-muenchen.de.
Department of Medicine, Technical University of Munich, Munich, Germany. heiko.lickert@helmholtz-muenchen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH